TGFB2 and breast carcinoma: These observations led us to hypothesize that ezetimibe restrains breast cancer cell migration and invasion by nullifying the angiogenic consequences of TGFβ2 and increasing perivascular cell coverage by trimming cholesterol absorption levels.